Egyptian healthtech startup Reme-D has raised $1.45 million in a pre-Series A funding round led by Anara Impact Capital to expand production of its molecular diagnostic tests and grow its presence across Africa and other underserved markets.
The round included participation from the Global Innovation Fund, Africa Health Ventures, and other investors. The funding follows a $500,000 investment from the Global Innovation Fund in April and will support higher manufacturing capacity, regional expansion, and the development of new diagnostic products.
Founded in 2023 by Salma Tammam, Reme-D develops molecular diagnostic tests for diseases including tuberculosis, HIV, hepatitis, and human papillomavirus (HPV). Its products are designed to remain stable at higher temperatures, reducing the need for cold-chain storage and making them easier to distribute in remote areas with limited healthcare infrastructure.
Since launching, the Cairo-based company has developed and commercialized 30 diagnostic products and supplied more than 550,000 tests across Egypt, Kenya, and Sudan. Reme-D also recently equipped a solar-powered mobile laboratory commissioned by the World Health Organization’s Egypt office to support the country’s monitoring of vector-borne diseases. The company plans to move into a new 1,500-square-meter manufacturing facility, increasing production capacity tenfold while expanding into diagnostics for genetic diseases and cancer.